<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182778</url>
  </required_header>
  <id_info>
    <org_study_id>KHBO1401</org_study_id>
    <secondary_id>UMIN 000014371</secondary_id>
    <nct_id>NCT02182778</nct_id>
  </id_info>
  <brief_title>GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer</brief_title>
  <official_title>Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kansai Hepatobiliary Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kansai Hepatobiliary Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To validate the superiority of Gemcitabine/Cisplatin/S-1 over Gemcitabine/Cisplatin for
      unresectable biliary tract cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine/cisplatin combination therapy (GC) has been the standard palliative chemotherapy
      for patients with advanced biliary tract cancer (BTC). Investigators have evaluated the
      efficacy and safety of gemcitabine/cisplatin/S-1 combination therapy (GCS) for patients with
      advanced BTC and observed the promising efficacy. In this randomized phase â…¢ study,
      investigators aimed to compare GCS with GC in patients with advanced BTC.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>Probability of 1-year survival (%)</time_frame>
    <description>The primary endpoint is designated to evaluate overall survival rate at 12-month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Every 3 months, up to 24 months</time_frame>
    <description>The investigators will conduct CT test every 3 months in order to measure the tumor size of each patient and evaluate the best tumor response according to RECIST criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Every 3 months, up to 24 months</time_frame>
    <description>In oredr to research the progression survival, the investigators will check the presence of progression disease for each patient every three months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>24 months</time_frame>
    <description>The investigators will examine the frequency and the degree of each side effect that will appear to the patient at each course of chemotherapy .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine/Cisplatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine/Cisplatin /S-1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Cisplatin</intervention_name>
    <description>Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.</description>
    <arm_group_label>Gemcitabine/Cisplatin /S-1 group</arm_group_label>
    <other_name>Gemcitabine;gemzer, Cisplatin;Cispulan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/Cisplatin /S-1</intervention_name>
    <description>S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.</description>
    <arm_group_label>Gemcitabine/Cisplatin group</arm_group_label>
    <other_name>Gemcitabine;gemzer, Cisplatin;Cispulan S-1;TS-1,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with cytologically or histologically proved biliary tract cancer

          2. age &gt;=20 years

          3. Performance Status (PS) 0-2

          4. No prior history of chemotherapy or radiotherapy.

          5. Adequate bone marrow function (neutrophil count &gt;=1,500/mm3, and platelet count
             &gt;=100,000/mm3), liver function (total bilirubin &gt;=3 mg/dL and AST/ALT &gt;=150 IU/L), and
             renal function (creatinine clearance &gt;=45 mL/min)

          6. Adequate oral intake

          7. Provided written informed consent -

        Exclusion Criteria:

          1. Patients with interstitial pneumonia or pulmonary fibrosis

          2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a
             new onset of myocardial infarction within 3 months

          3. Patients with severe active infection

          4. Patients with moderate or marked pleural effusion or ascites necessitating drainage

          5. Patients with a history of severe drug allergy

          6. Patients with other serious comorbid disease

          7. Patients who are pregnant or lactating, or have an intention to get pregnant

          8. Patients with mental disease

          9. Patients who are judged inappropriate for the entry into the study by the principle
             doctor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masashi Kanai</last_name>
    <role>Study Director</role>
    <affiliation>Kyoto University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>October 5, 2017</last_update_submitted>
  <last_update_submitted_qc>October 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>S 1 (combination)</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

